Global Patient Derived Xenograft (PDX) Models Market Segmentation, By Type (Mice Models, Rat Models), Tumor Type (Respiratory Tumor Models, Urological Tumor Models, Gastrointestinal Tumor Models, Hematological Tumor Models, Gynecological Tumor Models, Others), Application (Preclinical Drug Development and Oncology Research, Biomarker Analysis), End User (Contract Research Organization, Academic and Research Institutions, Pharmaceutical and Biotechnology Companies) – Industry Trends and Forecast to 2031
Patient Derived Xenograft (PDX) Models Market Analysis
Xenograft tumor models are known to preserve original tumor characteristics including, clinical biomolecular signature, tumor archive, heterogeneous histology, and malignant phenotypes and génotypes, among others.
Patient Derived Xenograft (PDX) Models Market Size
Global patient derived xenograft (PDX) models market size was valued at USD 194.95 billion in 2023 and is projected to reach USD 685.03 billion by 2031, with a CAGR of 17.01% during the forecast period of 2024 to 2031.
Report Scope and Market Segmentation
|
Attributes
|
Patient Derived Xenograft (PDX) Models Key Market Insights
|
|
Segmentation
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Key Market Players
|
Crown Bioscience Inc. (US), THE JACKSON LABORATORY (US), Champions Oncology, Inc. (US), Charles River Laboratories (US), Wuxi AppTec (China), Oncodesign (Canada), Aragen Bioscience (India), Biocytogen (US), Bioduro (US), Creative Animodel (US), Covance Inc. (US), EPO Berlin-Buch GmbH (Germany), EUROPDX. (Belgium), Explora BioLabs (US), Hera BioLabs (US), Horizon discovery Ltd. (UK), Pharmatest Services (Finland), Urospehere SAS (Cyprus), Xentech (France), Xenopat (France) among others
|
|
Market Opportunities
|
|
Patient Derived Xenograft (PDX) Models Market Definition
Patient-derived xenografts (PDX) refer to the models of cancer where cells or tissues from a tumor of a patient that are implanted into humanized or immunedeficient mouse. These models are known to simulate human tumor biology that enables natural cancer progression. This provides translational research model in order to evaluate efficacy.
Patient Derived Xenograft (PDX) Models Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:
- Demand for Personalized Medicine
The increase in demand for personalized medicine across the globe acts as one of the major factors driving the growth of patient derived xenograft (PDX) models market.
- Continuous Support for Cancer Research
The continuous support for cancer research from the public and private sectors in the form of funds and investments accelerate the market growth.
- Research and Development
The surge in the number of research and development activities to enhance the treatment options available further influence the market.
Opportunities
Furthermore, rise in demand for humanized PDX models extend profitable opportunities to the market players in the forecast period of 2024 to 2031. Also, technological development will further expand the market.
Restraints/Challenges
On the other hand, high cost associated with the personalized PDX models and stringent guidelines for the use of animal models in cancer research are expected to obstruct market growth. Also, limitations of PDX models are projected to challenge the patient derived xenograft (PDX) models market in the forecast period of 2024-2031.
This patient derived xenograft (PDX) models market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on patient derived xenograft (PDX) models market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Patient Derived Xenograft (PDX) Models Market
Covid-19 had a negative impact on the patient derived xenograft (PDX) models market owing to the decline in the productivity in life science organizations during the pandemic. The reduction in pharma research and development deals in therapeutic areas, disruption of clinical trials and country-wise lockdowns also impacted the market. The most affected trials were associated with oncology, ID/anti-infectives, cardiovascular disease and respiratory disease. The market will regain its growth the impact of COVID-19 is expected to diminish during the post-pandemic scenario.
Patient Derived Xenograft (PDX) Models Market Scope
The patient derived xenograft (PDX) models market is segmented on the basis of type, tumor type, application, technique and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Mice Models
- Rat Models
Tumor Type
- Gastrointestinal Tumor Models
- Lung Tumor Models
- Haematological Tumor Models
- Gynecological Tumor Models
- Respiratory Tumor Models
- Urological Tumor Models
- Others
Application
- Preclinical Drug Development
- Precision Medicine
- Co-Clinical Trials
- Basic Cancer Research
Technique
- Heterotopic Implantation
- Orthotropic Implantation
End User
- Academic and Research Organizations
- Contract Research Organizations
- Pharmaceutical and Biotechnological Companies
- Others
Patient Derived Xenograft (PDX) Models Market Regional Analysis
The patient derived xenograft (PDX) models market is analysed and market size insights and trends are provided by country, type, tumor type, application, technique and end user as referenced above.
The countries covered in the patient derived xenograft (PDX) models market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the patient derived xenograft (PDX) models market because of the increase in the research activity in cancer and stem cells within the region.
Asia-Pacific (APAC) is expected to witness significant growth during the forecast period of 2024 to 2031 due to the rising incidence of cancer in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Patient Derived Xenograft (PDX) Models Market Share
The patient derived xenograft (PDX) models market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to patient derived xenograft (PDX) models market.
Patient Derived Xenograft (PDX) Models Market Leaders Operating in the Market Are:
- Crown Bioscience Inc. (US)
- THE JACKSON LABORATORY (US)
- Champions Oncology, Inc. (US)
- Charles River Laboratories (US)
- Wuxi AppTec (China)
- Oncodesign (Canada)
- Aragen Bioscience (India)
- Biocytogen (US)
- Bioduro (US)
- Creative Animodel (US)
- Covance Inc. (US)
- EPO Berlin-Buch GmbH (Germany)
- EUROPDX. (Belgium)
- Explora BioLabs (US)
- Hera BioLabs (US)
- Horizon discovery Ltd. (UK)
- Pharmatest Services (Finland)
- Urospehere SAS (Cyprus)
- Xentech (France)
- Xenopat (France)
Latest Developments in Patient Derived Xenograft (PDX) Models Market
- Collagen Matrix, Inc., a global leader collagen-based, regenerative, xenograft-derived medical devices, and Linden Capital Partners (“Linden”) announced the acquisition of Sunstar’s Degradable Solutions division. It included GUIDOR branded line of resorbable synthetic medical implants. The purpose behind the acquisition is expanding the range of technologies offered to the customers.
SKU-